

## PRESS RELEASE

# DIGNITANA

### Media Contact – US

Caren Browning  
King + Company  
00 1 212 561 7464  
[Caren.Browning@kingcompr.com](mailto:Caren.Browning@kingcompr.com)

### Media Contact – Sweden

Anja Trägårdh  
Trägårdh Kommunikation  
+46 70 934 6664  
[anja@tragardhkommunikation.se](mailto:anja@tragardhkommunikation.se)

### Corporate Contact

Johan Ericsson  
Chief Executive Officer  
+46 46 16 30 92  
[johan.ericsson@dignitana.se](mailto:johan.ericsson@dignitana.se)

## **DIGNITANA SIGNS ON *DIGNITY HEALTH* AS GROWTH CONTINUES IN U.S.**

### **One of the Largest Health Systems in America Will Provide DigniCap® Scalp Cooling System to Cancer Patients to Reduce Chemotherapy Hair Loss**

**Lund, Sweden – August 4, 2017** - Dignitana AB, a world leader in medical scalp cooling technology and manufacturer of the DigniCap® Scalp Cooling System, announced today that Dignity Health, the fifth largest health system in the nation and the largest hospital provider in California, will offer DigniCap® to patients in its diverse health network. Headquartered in San Francisco, [Dignity Health](#) is made up of more than 60,000 caregivers and staff who deliver care in 22 states.

In the United States, DigniCap® is [available](#) at 87 cancer clinics in 21 states, helping thousands of patients each year minimize chemotherapy-induced hair loss.

“To be selected as the provider of scalp cooling therapeutics for one of the largest health networks in the U.S. is a tremendous honor,” said William Cronin, Chief Executive Officer of Dignitana, Inc. “We are proud to add this distinctive partnership to the list of patient-focused healthcare centers who are making it possible for cancer patients to avoid losing their hair as a result of chemotherapy. We look forward to working with the experienced clinicians in the Dignity Health system.”

Last month, the U.S. Food and Drug Administration [announced expanded indications](#) for DigniCap® allowing use by men and women receiving chemotherapy for solid tumor cancers. Previous clearance was limited to women with breast cancer. As the first and only device FDA-cleared for use with solid tumor cancers, medical facilities in the U.S. may now use DigniCap® to reduce hair loss in patients treated for solid tumor cancers such as breast, prostate, ovary, uterus, lungs and other tissues. This expands the potential reach for the device to approximately 800,000 cancer patients annually ([cancer.org](#)).

Positive results from a multi-center clinical trial published in February 2017 by [The Journal of the American Medical Association](#) (JAMA), indicate that 66.3% of patients using DigniCap® retained at least 50% of their hair.

#### **About Dignitana AB (publ)**

Dignitana is a Swedish public company based in Lund and manufacturer of the medical cooling device DigniCap®. Dignitana AB is listed on Nasdaq First North Stockholm and has appointed Erik Penser Bank as Certified Adviser. Headquartered in Dallas Texas, **Dignitana, Inc.** is the U.S. subsidiary of Dignitana AB. For more information visit [www.dignitana.se](http://www.dignitana.se)

#### **About The DigniCap® Scalp Cooling System**

DigniCap® is a patented scalp cooling system that offers cancer patients the ability to keep their hair during chemotherapy. DigniCap® provides continuous cooling with high efficacy, safety and acceptable patient comfort. [www.dignicap.com](http://www.dignicap.com)

#### **About Dignity Health**

Dignity Health, one of the nation’s largest health care systems, is a 22-state network of more than 9,000 physicians, 62,000 employees, and 400 care centers, including hospitals, urgent and occupational care, imaging centers, home health, and primary care clinics. Headquartered in San Francisco, Dignity Health is dedicated to providing compassionate, high-quality, and affordable patient-centered care with special attention to the poor and underserved. In FY16, Dignity Health provided \$2.2 billion in charitable care and services. For more information, please visit [www.dignityhealth.org](http://www.dignityhealth.org).

***This information is information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the above contact, for publication at 08:45 CET, 4 August, 2017.***